Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01816971 · OUTCOME

Percentage of Participants With Overall Survival (OS)

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2026-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Up to 5 years

What was measured

Overall survival rate was estimated at months 12, 24, 36, 48, and 60, by the product-limit method of Kaplan and Meier.

Groups in this outcome

Treatment (Dexamethasone, Carfilzomib, Lenalidomide)

INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.. TRANSPLANT: Patients undergo autologous stem cell transplant. CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity. dexamethasone: Given IV or PO carfilzomib: Given IV lenalidomide: Given PO autologous hematopoietic stem cell transplantation: Undergo autologous hematopoietic stem cell transplant laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Dexamethasone, Carfilzomib, Lenalidomide)76

Reported measurements

OS rate at 12 months (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Dexamethasone, Carfilzomib, Lenalidomide)100Not reportedNot reportedNot reportedNot reported
OS rate at 24 months (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Dexamethasone, Carfilzomib, Lenalidomide)97Not reportedNot reportedNot reportedNot reported
OS rate at 36 months (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Dexamethasone, Carfilzomib, Lenalidomide)96Not reportedNot reportedNot reportedNot reported
OS rate at 48 months (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Dexamethasone, Carfilzomib, Lenalidomide)93Not reportedNot reportedNot reportedNot reported
OS rate at 60 months (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Dexamethasone, Carfilzomib, Lenalidomide)84Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        100
    title
    OS rate at 12 months (%)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        97
    title
    OS rate at 24 months (%)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        96
    title
    OS rate at 36 months (%)
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        93
    title
    OS rate at 48 months (%)
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        84
    title
    OS rate at 60 months (%)
denoms
  1. counts
    1. group Id
      OG000
      value
      76
    units
    Participants
description
Overall survival rate was estimated at months 12, 24, 36, 48, and 60, by the product-limit method of Kaplan and Meier.
groups
  1. description
    INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.. TRANSPLANT: Patients undergo autologous stem cell transplant. CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity. dexamethasone: Given IV or PO carfilzomib: Given IV lenalidomide: Given PO autologous hematopoietic stem cell transplantation: Undergo autologous hematopoietic stem cell transplant laboratory biomarker analysis: Correlative studies
    id
    OG000
    title
    Treatment (Dexamethasone, Carfilzomib, Lenalidomide)
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 5 years
title
Percentage of Participants With Overall Survival (OS)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice